| 0.0109 -0.001 (-5.22%) | 05-10 15:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.01  |
1-year : | 0.01 |
| Resists | First : | 0.01 |
Second : | 0.01 |
| Pivot price | 0 |
|||
| Supports | First : | 0 |
Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0 |
| MA(100) : | 0.11 |
MA(250) : | 0.37 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.5 |
D(3) : | 44 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 1.35 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BTTX ] has closed below upper band by 37.9%. Bollinger Bands are 91.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Wed, 20 Mar 2024
BTTX Stock Price and Chart — OTC:BTTX — TradingView - TradingView
Fri, 15 Mar 2024
Better Therapeutics Overhaul and Nasdaq Delisting - TipRanks.com - TipRanks
Thu, 14 Mar 2024
Better Therapeutics plans employee layoffs, strategic review By Investing.com - Investing.com
Thu, 14 Mar 2024
Digital diabetes app maker Better Therapeutics shutters operations, lays off staff - Fierce Biotech
Thu, 14 Mar 2024
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Business Wire
Thu, 14 Mar 2024
Better Therapeutics Shutters Operations, Terminates Employees, NASDAQ Delisting - HIT Consultant
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 53.3 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 2,130 (K) |
| Shares Short P.Month | 961 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|